Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth. (Record no. 25926477)

MARC details
000 -LEADER
fixed length control field 01524 a2200385 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250517091626.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201608s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1349-7006
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1111/cas.12903
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Sanches, Jéssica de Souza
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 20160825
245 00 - TITLE STATEMENT
Title Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth.
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Cancer science
Date of publication, distribution, etc. Apr 2016
300 ## - PHYSICAL DESCRIPTION
Extent 551-5 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Journal Article; Research Support, Non-U.S. Gov't
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Angiogenesis Inhibitors
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Animals
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antibodies, Anti-Idiotypic
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antibodies, Monoclonal
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Bevacizumab
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cell Line, Tumor
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Melanoma, Experimental
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Mice
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Neovascularization, Pathologic
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Vascular Endothelial Growth Factor A
General subdivision immunology
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name de Aguiar, Rodrigo Barbosa
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Parise, Carolina Bellini
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Suzuki, Juliana Mayumi
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Chammas, Roger
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name de Moraes, Jane Zveiter
773 0# - HOST ITEM ENTRY
Title Cancer science
Related parts vol. 107
-- no. 4
-- p. 551-5
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1111/cas.12903">https://doi.org/10.1111/cas.12903</a>
Public note Available from publisher's website

No items available.